Royalty Pharma: Q2 Earnings Insights

  Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

 

Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Royalty Pharma missed estimated earnings by 10.26%, reporting an EPS of $0.7 versus an estimate of $0.78.

Revenue was down $19.05 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.13 which was followed by a 2.58% drop in the share price the next day.

Here’s a look at Royalty Pharma’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.73 0.77   0.69
EPS Actual 0.60 0.80 0.24 0.73
Revenue Estimate 599.76M 556.79M 578.20M 483.42M
Revenue Actual 562.00M 576.00M 585.77M 555.00M

To track all earnings releases for Royalty Pharma visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Haynes International Updates Operational Restorations Regarding Its Operational Restoration Efforts Following The Recent Cybersecurity Incident; Not Yet Possible To Determine The Full Impact On The Company’s Quarterly Financial Results

Haynes International, Inc. (NASDAQ GM: HAYN) (the "Company"), a leading developer, manufacturer and marketer of technologically advanced high-performance alloys, provided an update today regarding its

HAYN

Read More

Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meetin…

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a

EGRX